CTR launches podcast together with SwedenBIO

The first episode of the podcast Idé till patient (Idea to patient) will be released on April 12.

The podcast series is a co-production between the companies within the CTR-group and SwedenBIO. The series comprises six episodes where invited guests from the pharma industry will be discussing the pitfalls and highlights in early drug development. Episodes 2-4 will mirror the way to clinical trials and episode 5 will comprise discussions about the first-in-human trial.

“We will discuss important keys in how to go from idea to patient. We highlight the importance of having a TPP early on, need to plan for toxicology early, how to interpret guidelines and how to choose starting dose in your first in human study”, says Karin Meyer, CEO at CTR.

“SwedenBIO encourage member companies to share knowledge and experiences with each other in the Life Science community and we are happy to launch this podcast with the CTR companies. The translational phase from idea to a new treatment for the patient is complex. With the podcast we hope to untangle the obstacles in an easy-going way”, says Frida Lawenius, Deputy Director General at SwedenBIO.

Center for Translational Research Sweden

CTR was founded 2016 and is a group of complementary life science service companies engaged in translational research. CTR is the owner of Clinical Trial Consultants, RegSmart Life Science, RegFile, Lablytica Life Science and Toxicology Knowledge Team Sweden.

SwedenBIO

SwedenBIO is the national non-profit association for the life science industry in Sweden, with more than 300 members. Sweden has an innovative life science industry, strong academia and world leading infrastructure for research. SwedenBIO’s members are companies active within pharma, biotech, diagnostics and medtech and comprise the entire range from small start-ups, to SMEs and large enterprises. Many are engaged in research and development. Other members are experts in fields such as IP, law, finance, product development, life science communication, and business development.